MorrisonRJHollisterSJNiednerMF, et al. Mitigation of tracheobronchomalacia with 3D-printed personalized medical devices in pediatric patients. Sci Transl Med. 2015;7:285ra64.
2.
YoungermanBEMcKhannGMII. Innovation in surgery and evidence development: can we have both at once?Virtual Mentor. 2015;17:41-48.
3.
JarowJPLuriePIkenberrySCLemeryS. Overview of FDA’s expanded access program for investigational drugs. Ther Innov Regul Sci. 2017;51:177-179.
4.
JarowJPLemerySBuginKKhozinSMoscickiR. Expanded access of investigational drugs: the experience of the Center of Drug Evaluation and Research over a 10-year period. Ther Innov Regul Sci. 2016;50:705-709.
5.
LantosJD. The regulation of clinical research: what’s love got to do with it?Learn Health Syst. 2018;2:e10048.
6.
Spector-BagdadyKWeatherwaxKJGravelinMShumanAG. The critical role of medical institutions in expanding access to investigational interventions. Hastings Cent Rep. 2019;49:36-39.
BeecherHK. Ethics and clinical research. N Engl J Med. 1966;274:1354-1360.
10.
Spector-BagdadyKLombardoPA. U.S. Public Health Service STD experiments in Guatemala (1946-1948) and their aftermath. Ethics Hum Res. 2019;41:29-34.
11.
MarchianoEJBirkelandACSwiecickiPLSpector-BagdadyKShumanAG. Revisiting expectations in an era of precision oncology. Oncologist. 2018;23:386-388.
12.
WeinfurtKPSeilsDMLinL, et al. Research participants’ high expectations of benefit in early-phase oncology trials: are we asking the right question?J Clin Oncol. 2012;30:4396-4400.
13.
SulmasyDPAstrowABHeMK, et al. The culture of faith and hope: patients’ justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer. 2010;116:3702-3711.
